GlassScriptPhysician profile
Jeremy Timmer
NPI 1992731459
$2,444.57
in general payments reported to CMS, 2019-2025
27 companies · $247 in 2025
The $247 reported for 2025 was more than what a typical Surgical Critical Care provider received nationally (typical 2025 total: $234).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $315 · 2021: $90.47 · 2022: $226 · 2023: $702 · 2024: $534 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,483.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $888.39 | 2019-2025 | Trumatch, Xcm Biologic Tissue Matrix, Matrixrib |
| Kerecis Limited | $319.47 | 2022-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Teleflex LLC | $135.09 | 2023 | Quikclot |
| Pfizer INC. | $93.59 | 2019-2020 | |
| Haemonetics Corporation | $89.97 | 2023-2025 | Teg6s Hemostasis System |
| Biocomposites INC | $87.50 | 2024 | |
| Ethicon US, LLC | $85.66 | 2020-2022 | |
| Allergan, INC. | $82.36 | 2020-2022 | |
| Z-Medica, LLC | $75.87 | 2019 | |
| Medical Device Business Services, INC. | $72.90 | 2024 | Matrixrib |
| Takeda Pharmaceuticals U.S.A., INC. | $66.53 | 2023-2024 | Gattex |
| Aroa Biosurgery Incorporated | $58.46 | 2024 | |
| Davol INC. | $54.85 | 2019-2025 | Phasix Mesh |
| Galderma Laboratories, L.P. | $50.34 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $36.12 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $34.44 | 2019 | |
| Abbvie INC. | $30.02 | 2023-2025 | Strattice Reconstructive Tissue Matrix Bps |
| Innovation Technologies INC | $25.24 | 2025 | Irrisept |
| Becton, Dickinson and Company | $22.48 | 2023 | Phasix Mesh |
| Molnlycke Health Care US, LLC | $20.73 | 2023 | Mepilex Transfer, Mepilex Border Post-Op, Mepilex |
| Smith+Nephew, INC. | $17.98 | 2023 | Regranex, Collagenase Santyl |
| Lifenet Health | $17.96 | 2025 | Theragenesis Wound Matrix |
| Polynovo North America LLC | $17.90 | 2020 | |
| Mallinckrodt Enterprises LLC | $17.84 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.58 | 2023 | Seglentis |
| Solventum Corporation | $14.49 | 2024 | V.A.C. Veraflo Cleanse Choice |
| Kci USA, INC. | $12.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Timmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.